Ata uhi

Prediction of drug concentrations in humans for long-acting injectable suspensions by a semi-mechanical muscle compartment model: a case study of paliperidone palmitate

I tiakina i:
I whakaputaina i:Frontiers in Pharmacology vol. 16 (Jul 2025), p. 1507828-1507840
Kaituhi matua: Yu, Panpan
Ētahi atu kaituhi: Zhang, Mengjun, Xiong, Jin, Wu, Keheng, Long, Sihui, Cheng, Shishi, Long, Fu, Xu, Xiao, Liu, Jie, Liu, Dan, Li, Xue, Liu, Bo, Xu, Jian
I whakaputaina:
Frontiers Media SA
Ngā marau:
Diffusion coefficient
Dissolution
Pharmacokinetics
Physicochemical properties
Drug development
Nanocrystals
Computer simulation
Particle size
Anticoagulants
Metabolism
Palmitic acid
Dogs
Drug dosages
Urunga tuihono:Citation/Abstract
Full Text
Full Text - PDF
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
Whakarāpopotonga:Long-acting injectable formulations, such as paliperidone palmitate extended-release injectable suspension, have been designed to release medicines slowly and sustainably. Developing models that simulate drug release from long-acting injectable formulations in vivo is challenging. A novel approach to modeling and simulating complex and multiphasic drug pharmacokinetics (PK) is provided in this article to facilitate development of long-acting formulations. By segmenting nanocrystalline particles according to their different sizes, the absorption delays of each segment were obtained from the results of the PK study in dogs. In addition to the lag time for each segment, all other parameters, including physicochemical parameters such as drug solubility, density and diffusion coefficient, as well as pharmacokinetic parameters related to clearance, elimination and distribution, were introduced into the model to establish a muscle compartment model for use in humans. By using this model, the injectable suspensions paliperidone samples were predicted to have a long release of 90–100 days in vivo .
ISSN:1663-9812
DOI:1507828
Puna:Biological Science Database